



This is a marketing communication.

September 2019

INVESTMENT OBJECTIVE

The objective of the GAMCO Merger Arbitrage Sub-Fund is to achieve long-term capital growth by investing primarily in announced equity merger and acquisition transactions while maintaining a diversified portfolio. The Fund utilizes a highly specialized investment approach designed principally to profit from the successful completion of proposed mergers, takeovers, tender offers, leveraged buyouts and other types of corporate reorganizations.

MONTHLY COMMENTARY

In September, we realized gains on several deals that closed, while other transactions made notable progress towards completion. We have a full pipeline of invested deals, and we remain busy deploying (y)our capital in transactions with attractive return profiles and clear paths to closing.

Noteworthy Announced Deal in the Month of September

Alder BioPharmaceuticals, Inc. (ALDR-\$18.86-NASDAQ) agreed to be acquired by H. Lundbeck A/S (LUN DC-DKK227.20-Copenhagen). Alder BioPharmaceuticals operates as a clinical-stage biopharmaceutical company engaged in the development of therapeutic antibodies to transform migraine treatment. Under terms of the agreement Alder shareholders will receive \$18.00 cash per share, valuing the transaction at approximately \$2 billion. The agreement also includes a Contingent Value Right ("CVR") of \$2.00 per share which will be paid upon the European Medicines Agency's approval of Alder's migraine prevention drug, eptinezumab. The transaction is subject to the tender of at least a majority of shares outstanding, as well as regulatory approval and is expected to close in the fourth quarter of 2019.

Noteworthy Completed Deal in the Month of September

Oaktree Capital Group LLC (OAK-NYSE) - Brookfield Asset Management, Inc. (BAM-\$53.09-NYSE) completed its acquisition of Oaktree in September. Oaktree is an investment manager specializing in alternative investments with approximately \$120 billion in assets under management at the end of 2018. On March 13th, 2019, Brookfield announced it would acquire Oaktree with a premium at announcement of approximately 12%. The terms of the transaction entitled Oaktree shareholders to receive, on a pro-rated basis, \$49.00 cash or 1.0770 shares of Brookfield Class A stock per share, valuing the transaction at approximately \$4 billion.

SUB-FUND OVERVIEW

Legal Structure	Luxembourg SICAV
Fund Launch Date	October 2011
Strategy Launch Date	January 1985
Base Currency	USD
Available Currency Classes	EUR, CHF, GBP, SEK

ISIN Class I (EUR)	LU0687944396
Bloomberg Code	GAMMAIE LX
Investment Manager	Gabelli Funds, LLC
Administrator	RBC Investor Services Bank S.A.
Liquidity	Daily
Subscription/Redemption Notice	4.00 PM CET
Settlement Period	D + 3

Total Fund Assets (USD)	\$533 mn
Strategy Assets (USD)	\$1,466 mn
Management Fee	1.00%
Performance Fee	15% with HWM & Hurdle ²

PORTFOLIO EXPOSURE

Long	104%
Short	15%
Gross	119%
Net	89%

PERFORMANCE (%)³ [Annualized 1Y, 3Y, 5Y]

	1 Month	3 Months	1 Year	3 Year	5 Year
GAMCO Merger Arbitrage - I EUR	0.27	0.38	0.99	0.78	1.87
Credit Suisse Merger Arbitrage Liquid Index ¹	0.38	1.31	4.77	4.26	2.45


PERFORMANCE TABLE³ [% NET OF EXPENSES]

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD
2019	1.31	0.14	0.35	0.09	-1.18	0.38	0.35	-0.24	0.27				1.46
2018	0.69	-0.41	-1.28	-0.91	1.36	0.85	-0.84	0.26	0.34	-1.78	1.77	-0.43	0.69
2017	-1.46	0.40	-0.06	0.99	0.20	0.79	0.01	-0.63	0.32	0.21	-0.92	0.37	-1.46
2016	-0.09	0.23	1.34	-0.59	0.86	-0.14	0.11	0.70	0.65	-1.06	1.67	0.51	-0.09
2015	-0.57	1.94	0.33	0.46	0.61	-0.39	-0.51	-0.96	-1.12	2.10	0.33	0.71	-0.57
2014	2.26	0.34	-0.42	-0.28	1.08	0.91	-0.28	-0.01	-0.79	-0.51	1.26	0.27	2.26
2013	-3.39	4.56	2.26	-2.64	2.17	-0.16	-1.46	0.61	-1.82	-0.36	0.53	-1.60	-3.39
2012	-0.16	-1.67	0.32	0.33	6.27	-2.09	3.03	-2.19	-2.12	-2.77	0.53	0.40	-0.16
2011										-2.48	3.80	3.82	


Share class hedging vs USD was implemented in March 2014, prior performance is unhedged and reflects currency fluctuations

DISCRETE ANNUAL PERFORMANCE³

[IN SHARE CLASS CURRENCY]



CUMULATIVE PERFORMANCE³ [SINCE SHARE CLASS HEDGING IMPLEMENTATION - MAR 2014]



RISK ANALYSIS³

	Since Share Class Hedging Implementation (Mar-2014)	
	Fund	Index*
Volatility (%)	2.87	3.12
Sharpe Ratio	0.30	0.11
Maximum Drawdown (%)	-2.95	-7.67

*Credit Suisse Merger Arbitrage Liquid Index¹

IMPORTANT NOTE


Unless otherwise stated, performance is shown net of fees and expenses, on a NAV to NAV basis. For professional investors only.

¹ The Credit Suisse Merger Arbitrage Liquid Index seeks to gain broad exposure to the Merger Arbitrage strategy by using a pre-defined quantitative methodology in order to invest in a liquid, diversified and broadly representative set of announced merger deals. The index does not reflect the fundamental qualitative research into individual announced deals which the composition of the Sub-Fund's portfolio reflects. That difference in methodology may result in the performance divergence from the Sub-Fund. ² 20% incentive fee for base currency share classes and 15% for all non-base currency classes, subject to a high watermark and a hurdle rate of the 13 week Treasury Bills rate published by the US Treasury over the performance period. ³ These figures refer to the past and past performance are not a reliable indicator of future results. The performance calculation is in Euros. If your local currency is not Euros, you should be aware that due to exchange rate fluctuations, the performance shown may increase or decrease if converted into your local currency. The performance shown does not take into account any commission or costs that you may incur when subscribing to or redeeming shares. Please see risk considerations on the final page of this document.




60-DAY ANNUALIZED VOLATILITY⁴


[SINCE SHARE CLASS HEDGING IMPLEMENTATION – MAR 2014]




GEOGRAPHIC EXPOSURE (%)



MARKET CAP EXPOSURE (%)



SECTOR EXPOSURE (%)



NOTEWORTHY POSITIONS

Target / Acquirer*
Allergan, Inc. / AbbVie, Inc.
Buckeye Partners, LP
Celgene Corp. / Bristol Myers Squibb
Medidata Solutions, Inc.
Mellanox Technologies Ltd.
Suntrust Banks, Inc. / BB&T Corp.
Versum Materials, Inc.
Wabco Holdings, Inc.
Wellcare Health Plans, Inc. / Centene Corp.
Zayo Group Holdings, Inc.

*Acquirers are listed when acquirers' shares are offered as deal consideration and the Sub-Fund has shorted the acquirer's stock to lock in a spread.

PORTFOLIO BREAKDOWN

Deals	Positions	% of Assets
Cash Deals	47	67
Stock Deals	3	2
Cash and Stock Deals	5	15
Liquidations / Other	25	16
	80	100%

AVAILABLE SHARE CLASS ISIN⁵

Institutional		Retail	
Class I (USD)	LU0687944552	Class A (USD)	LU0687943745
Class I (EUR)	LU0687944396	Class A (EUR)	LU0687943661
Class I (CHF)	LU0687944719	Class A (CHF)	LU0687944123
Class I (GBP)	LU1453360585	Class A (SEK)	LU1268547574
Class I (GBP) unhedged	LU1453360668	Class R (GBP)	LU1453361476
Class I (SEK)	LU1218429717	Class R (EUR)	LU1453361129
		Class R (USD)	LU1453360825

IMPORTANT NOTE

⁴ Annualized volatility is a measure of the risk of price moves for a security calculated from the standard deviation of day to day, logarithmic historical price changes. The 60-day price volatility equals the annualized standard deviation of the relative price change for the 60 most recent trading days' closing price, expressed as a percentage.

⁵ While not currently active, the following currency classes are listed in the prospectus and can be launched at the discretion of the manager: NOK, DKK, KRW, TWD, SGD, YEN, AUD, HKD, and BRL. Individual share class launches other than the USD, CHF, EUR, GBP, and SEK classes are subject to investor demand. Currently Available Classes: I – Institutional class, A – Retail class, X – Investment Manager & Institutional class are currently available. Classes available subject to investor demand: C – U.S. Intermediary, N – U.S. Intermediary. For more detailed descriptions of the unique nature of each share class, please see the Fund's prospectus.



RISK CONSIDERATIONS

Investment Strategy Risk. The Sub-Fund's strategy generally involves buying the securities of the target of an announced merger or other type of takeover transaction and selling short the securities of the acquirer. The key risk of investing in an announced merger arbitrage strategy is if the transaction invested in fails to close, causing the securities of the target to fall in price and the securities of the acquirer to rise in price.

Derivatives and Leverage Risk. The value of some financial derivative instruments may fluctuate rapidly and certain financial derivative instruments may introduce leverage, which may result in the Sub-Fund losing a greater amount on such financial derivative instruments than the amount invested.

Non-U.S. Securities Risk. The Sub-Fund regularly invests in the securities of issuers organized outside the United States. Investments in these securities involve investment risks relating to political, social, and economic developments outside the U.S., and risks resulting from the regulatory differences between U.S. and non-U.S. issuers and markets. These risks are more pronounced in emerging markets countries.

Foreign Currency Transaction Risks. The Sub-Fund regularly invests in merger arbitrage transactions where wither the investment currency is non-US dollars or the proceeds from the closing of the transaction will be paid in non-US dollars. These non-US dollar denominated investments involve risks relating to changes in the relative value of the non-US dollar currency to the US dollar, fluctuations in interest rates in the countries issuing the non-US dollar currency and potential foreign government interference through regulation of local currency exchange markets, foreign investment, or particular transactions in foreign currency.

Class Currency Hedging Risk. While the Sub-Fund may attempt to hedge against currency fluctuations for non- U.S.Dollar denominated share classes, there can be no guarantee that the value of any such class will not be affected by fluctuations in the U.S. Dollar against the relevant currency.

DISCLAIMER

For professional investors only.

This material is confidential and is intended solely for the use of the person or persons to whom it is given or sent and may not be reproduced, copied or given, in whole or in part, to any other person. The material is not an invitation to subscribe and is by way of information only. Nothing contained herein constitutes investment, legal, tax or other advice nor is it to be solely relied on in making an investment or other decision. This material relates to GAMCO Merger Arbitrage, which is a sub-fund of GAMCO International SICAV (the "Company").

Shares of the Company are generally only available for purchase by persons who are not U.S. Persons, as such term is defined in Regulation S promulgated under the United States Securities Act of 1933, as amended (the "Act"). This document does not constitute an offer to anyone, or a solicitation by anyone, to subscribe for shares of the Company. The Company is a Luxembourg-registered UCITS. This material should be read in conjunction with the Company's prospectus (the "Prospectus") and the relevant key investor information document ("KIID"). All investment decisions should be based solely on the latest available Prospectus and local offering document (if applicable) which contain more information regarding charges, entry fees and minimum investment amount. A copy of the Prospectus, local offering document, KIID and the annual report, semi-annual report and the articles of incorporation of the Company are available free of charge upon request from RBC Investor Services Bank S.A.; 14, Porte de France, L-4360 Esch. sur Alzette, Grand-Duchy of Luxembourg Tel. +352 2605 9730, the Swiss Representative ACOLIN Fund Services AG, Affolternstrasse 56, CH 8050 Zurich, your financial adviser or your regional contact. More information is available at www.gabelli.com. The Prospectus is available in English and German, while the KIID is available in Dutch, English, French, German, Italian, Norwegian, Spanish and Swedish.

Additional Disclosures for Persons or Entities in the UK: This presentation is a marketing communication and has been issued for the purposes of United Kingdom Regulations by GAMCO Asset Management (UK) Limited ("GAMCO UK"). It is directed only at persons to whom it may be lawfully be communicated under Section 19 (Investment Professionals) of the Financial Services and Markets Act (Financial Promotions Order (2005) ("FPO") and is not to be distributed to retail investors. This communication relates to the GAMCO Merger Arbitrage, a Sub-Fund of the Company, which is qualified under the UCITs Directive, and is for information purposes only. Full details of the Company's objectives, investment policies and risks are located in the Prospectus which is available with the KIID in English. Potential investors should refer to the Prospectus and related documents prior to making a decision to invest. GAMCO UK is incorporated in England & Wales No: 197343 with a registered office and place of business at 64, St. James's Street, London, SW1A 1NF, United Kingdom. GAMCO Asset Management (UK) Limited is authorised and regulated by the Financial Conduct Authority ("FCA").

The information and any opinions have been obtained from or are based on sources believed to be reliable but accuracy cannot be guaranteed. No responsibility can be accepted for any consequential loss arising from the use of this information. The information is expressed at its date and is issued only to and directed only at those individuals who are permitted to receive such information in accordance with the applicable statutes. In some countries the distribution of this publication may be restricted. It is your responsibility to find out what those restrictions are and observe them. Past performance is not a reliable indicator of future results. Investments in Unregulated Collective Investment Schemes (UCIS) and in certain financial instruments referred to herein do carry a degree of higher risk and the value of your investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments.

GAMCO UK is a private limited company registered in England and Wales, registration number 197343. Registered office: 64 St. James Street, London SW1A 1NF and is authorised and regulated by the UK Financial Conduct Authority.

CHF and EUR share classes were not subject to the hedging of currency exposure between the respective share classes base currency denomination versus the currency denomination of portfolio holdings during the period commencing from the respective share classes inception date through January 30, 2014. From January 31, 2014 through the most current reported month-end, these share classes were subject to such currency hedging via the engagement of a professional third party currency hedging agent. Currency hedging techniques applied to hedged share classes may not entirely eliminate the effects of changes in exchange rates, therefore it cannot be guaranteed that the hedging objective will be achieved. Non-USD share classes are subject to such currency hedging via the engagement of a professional third party currency hedging agent. Currency hedging techniques applied to hedged share classes may not entirely eliminate the effects of changes in exchange rates, therefore it cannot be guaranteed that the hedging objective will be achieved.

Gabelli Funds, LLC is the investment manager for the Company and of U.S. open end and closed end funds business of GAMCO Investors, Inc. and its affiliated companies. Gabelli Funds, LLC is the trade name for the U.S. mutual fund business of GAMCO Investors, Inc. and its affiliated companies. All rights reserved.

Some of the statements in this material may contain or be based on forward looking statements, forecasts, estimates, projections, targets, or prognosis ("forward looking statements"), which reflect the manager's current view of future events, economic developments and financial performance. Such forward looking statements are typically indicated by the use of words which express an estimate, expectation, belief, target or forecast. Such forward looking statements are based on an assessment of historical economic data, on the experience and current plans of the investment manager and/or certain advisors of the manager, and on the indicated sources. These forward looking statements contain no representation or warranty of whatever kind that such future events will occur or that they will occur as described herein, or that such results will be achieved by the fund or the investments of the fund, as the occurrence of these events and the results of the fund are subject to various risks and uncertainties. The actual portfolio, and thus results, of the fund may differ substantially from those assumed in the forward looking statements. The manager and its affiliates will not undertake to update or review the forward looking statements contained in this presentation, whether as result of new information or any future event or otherwise. Past performance is not a reliable indicator of future results.